Call for Abstract

10th International Conference on Clinical Research & Clinical Trails , will be organized around the theme “Futuristic Approach towards the Enhancement of Clinical Trials & Clinical Research”

Euro Clinical Trails 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Euro Clinical Trails 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

The clinical trial market is enormous. To understand of its scale, and consider that the ClinicalTrials.gov currently lists more than the 280,000 active clinical research studies, and up from just 2,119 active studies in the year 2000. Even with these massive increase in the number of the clinical trials between 2000 and 2018,and the research indicates the market’s value will be also keep growing to reach the $65.2 billion by 2025.Despite  impressive size of the clinical trial market, and the industry faces the several challenges.

The primary challenge is undertaking a clinical trial  cost. A report from the U.S. Department of Health and Human Services estimates that the total cost across Phases I, II, III, and IV of a clinical trial can range from $44 million to $115.3 million, depending on the drug’s therapeutic area. Moreover, fewer than the  one in 10 drugs that are enter the clinical trials make it to the market.

  • Track 2-11.1:Improving Clinical Study Design
  • Track 2-21.2:Making It Easier to Match Patients with Clinical Trials
  • Track 2-31.3:Improving The Clinical Trial Enrollment Process
  • Track 2-41.4:Issues After Clinical Trial Enrollment
  • Track 2-51.5: Increasing Patient Adherence

\r\n The Clinical Data Management is the process of the handling data from the clinical trials. The inherent goal of a any clinical data management is the system is to produce and to maintain quality data.  And this department is to involved in the overall collection and in handling of the clinical trial data. And the Data Management teams that develop tools for collection of data at the clinical trial sites, and quality check the collected data for errors and raise flags in case of any discrepancy is identified. They develop the tools for the verification, validation and the quality control of the data gathered during the clinical trial. Clinical data managers to ensure the integrity and the confidentiality of collected data is to maintained at all the times. The Various security controls are to be incorporated into the system to ensure that the data extracted from the  clinical trials is to secure and not to prone to any open threats. The Careers in the Clinical Data Management are verypromising.in This field offers a wide scope of the career options.  At the Quanticate we believe  providing the high quality clinical data management to support the drug development needs to get the drugs to the market as quickly as possible. so the patients have access to the drugs. We provide bespoke solutions tailored to your requirements and provide real time, faster access to data meaning faster decisions can be made to keep patients as safe as possible.

\r\n

\r\n  

\r\n
  • Track 3-12.1 Clinical Data Management Certification
  • Track 3-22.2 Clinical Data Management Degree Programs
  • Track 3-32.3 Clinical Data Management Coursework & Specializations
  • Track 3-42.4 Associations & Resources for Clinical Data Management
  • Track 3-52.5 How Does Clinical Data Management (CDM) Work

\r\n The goal of a clinical research is to develop the generalize knowledge that  improves the human health or increases understanding of a human biology. People who can participate in the clinical research make it possible to secure that knowledge. The path is to finding out whether if a new drug or treatment is safe or effective, for example, to test it on the patient volunteers. But by placing a some people at risk of harm for the good of others, clinical research has a potential to exploit the patient volunteers. The purpose of the ethical guidelines is a both to protect patient volunteers and to the preserve to the integrity of a science.

\r\n

\r\n The ethical guidelines which is place today were primarily response to the past abuses, it was most notorious in which  America was an experiment in the Tuskegee, Alabama, in which the treatment was withheld from the 400 African American men with syphilis so that the scientists could study the course of a disease.A Various ethical guidelines were to developed in the 20th century in response to the such studies.

\r\n

\r\n  

\r\n

\r\n  

\r\n
  • Track 4-13.1 Social and clinical value
  • Track 4-23.2 Scientific validity
  • Track 4-33.3 Fair subject selection
  • Track 4-43.4 Favorable risk-benefit ratio
  • Track 4-53.5 Independent review

\r\n Identifying and addressing unmet patient needs is, and always will be, the ultimate goal of pharmaceutical R&D. Therefore the  new clinical trial models and  technologies behind them should be a harnessed to achieve those goals. In many cases, technology that allows constant monitoring of, and communication with, patients in real time creates the possibility to assess the results of therapies at a level of granularity and over a range of real-world conditions never before imagined – and to intervene in real time if necessary to improve patients’ lives.

\r\n

\r\n Clinical trials is often to serve as a first point of interaction between a patient and a sponsor company. Nevertheless, clinical teams can lose a sight of this fact when designing a technical components of a clinical studies. The outcome can be a cumbersome trial protocols adding a unnecessary burden on the patients and already in a challenging situation, and, therefore, unhappy patients, low recruitment and a high dropout rates, as well as a low scores on the company perception surveys.

\r\n

\r\n  

\r\n
  • Track 5-14.1 Create Patient Profiles
  • Track 5-24.2 Crowdsource Patients and Caregivers
  • Track 5-34.3 Monitor Online Opinions
  • Track 5-44.4 Work with the Experts to Mitigate Study Burden
  • Track 5-54.4 Work with the Experts to Mitigate Study Burden
  • Track 5-64.5 Simplify and standardize informed consent

\r\n Bioinformatics is a convergence of the biotechnology, genomics and information technology that analyses the data and even itrepresent in the statistical form.  It  even plays an important role in understanding the molecular works that is the basis of life. Bioinformatics is associated with the clinical trials are known as Clinical Bioinformatics. Understanding a relationship between the clinical informatics and a bioinformatics helps in discovering and developing the new diagnostics and therapies for diseases. The clinical application of a bioinformatics is associated with the science and technology and it is to understand molecular mechanism and potential therapies for human diseases.

\r\n

\r\n Clinical bioinformatics is a new and important concept for the development of a diseases-specific biomarkers, and the mechanism-oriented is to understanding and individualized medicine which provides a biological and medical a information to allow for  individualized healthcare. In this review,  we can describe the clinical bioinformatics and its application  and theoretical science. It is also about to understanding the molecular world that adds fuel to the life from evolutionary andmechanistic perspectives[6]Bioinformatics was originally developed for the analysis of biological sequences. But now, it encompasses a wide range of subject areas like structural biology, gene expression and genomics studies (figure1). Bioinformatics is  associated with the clinical trials which has gone through much depth of the studies on different subjects and has provided a number of ways that has never been imagined.

\r\n

\r\n  

\r\n
  • Track 6-1 5.1 Role in Drug Development
  • Track 6-25.2 Target Identification
  • Track 6-35.3 Quantitative structure activity relationship
  • Track 6-45.4 Software and bioinformatics tools in clinical trials
  • Track 6-55.5 Data management in clinical research

\r\n Clinical trials ar vital to the invention and development of innovative medicines that alter patients to measure longer, healthier lives. As the biopharmaceutical industry works to identify, test and bring new medicines to patients, clinical trials are instrumental in determining the safety and efficacy of a potential new treatment. 

\r\n

\r\n While clinical trials square measure long and complicated, innovative biopharmaceutical firms square measureinvesting the most recent scientific and technical advances to contour the method and make efficiencies. The use of novel trial designs and real-world evidence, for example, is helping to drive these advances, and recently passed legislation is helping to accelerate the uptake of these tools.

\r\n

\r\n As the pace of science continues to evolve, the drug development method – from discovery to approval – remains long and expensive.Developing a new medicine takes an average of 10 or additional years, and therefore the run element alone takes nearly six to seven years.Improving clinical trial design and efficiency thus presents an important challenge that deserves attention from all stakeholders.

\r\n

\r\n  

\r\n
  • Track 7-16.1 Clinical trials impact state economies
  • Track 7-26.2 The importance of diversity in clinical trials
  • Track 7-36.3 Bringing innovation to clinical trial design
  • Track 7-46.4 The Clinical trial experience from a patient & researcher perspective
  • Track 7-56.5 Advancing oncology research through clinical trials

\r\n A potentially radical solution is the conundrum of a patient recruitment and it is a deceptively simple idea – healthcare professionals which offering a clinical trial to the patients as one care option among many. The idea delivers the triple aim of improved patient experience of care, better population health and reduced per-capita healthcare costs, say some proponents. But what does ‘care option’ mean when talking about drugs that are still in development?

\r\n

\r\n In clinical trials, the drugs are not proven completely safe and efficacious, so we cannot say that a drug is going to treat a patient, as we are still trying to prove it.

\r\n

\r\n With four-out-of-five clinical trials failing to meet the original recruitment targets, a new approaches are needed

\r\n

\r\n “Patients, and especially patients with chronic conditions or life-threatening diseases, are often  looking for a solution, a treatment that may help to improve their quality of life or extend their life. Delays in the clinical trials can cause significant problems to the patients.”

\r\n

\r\n  

\r\n
  • Track 8-17.1 Creating a Patient Trial Community
  • Track 8-27.2 Bringing the Clinical Trial to the Patient
  • Track 8-37.3 Acquisitions as a strategy to get patient data
  • Track 8-47.4 The EHR interoperability challenge

\r\n Clinical and Medical Case Reports is an Open Access and the Scientific Journal that offers is an interesting publishing platform globally and the aims to keep scientists, clinicians, medical practitioners, researchers, and students updated on the ongoing research in the relevant area.Outstanding quality articles are welcome to maintain the highest standard of the journal and to achieve high impact factor.

\r\n

\r\n Clinical and the

\r\n

\r\n  Medical Case Reports is a peer reviewed Journal which that publishes novel research work conducted as case reports in the medical field in various types of Cases,for covering their respective clinical and diagnosis issues

\r\n

\r\n  

\r\n
  • Track 9-18.1 Allergy & Immunology Case reports
  • Track 9-28.2 Case reports of Neurology
  • Track 9-38.3 Case reports of Anesthesiology
  • Track 9-48.4 Dentistry and Oral Medicine Case reports
  • Track 9-58.5 Gastroenterology Case reports

\r\n Drug safety (also known as pharmacovigilance), is the science of detection, assessment, understanding and prevention of side effects which allows us to understand more about the risks and benefits of a medicine. 

\r\n

\r\n Adversed drug reactions experienced with the use of  medicinal product may result in the significant morbidity and mortality. The ultimate goal of pharmacovigilance is to ensure safe use of medicines, minimizing the risks related to the medicinal product and maximizing the benefits. During development of a medicinal product, it undergoes animal testing and establishing its safety and efficacy in humans before permission to market is granted. However, clinical trials are conducted on a small number of patients, ranging to a few thousand, and excluding special populations, e.g., children, pregnant and lactating women, and geriatric patients. 

\r\n

\r\n  

\r\n
  • Track 10-19.1 Discovering New Medicines
  • Track 10-29.2 Preclinical Safety
  • Track 10-39.3 Translational Medicine
  • Track 10-49.4 Early stage clinical trials
  • Track 10-59.5 Tool compounds and repurposing

\r\n Artificial intelligence could improve key parts of the clinical trial process, including selection and recruitment and patient monitoring, according to a study published in Trends in Pharmacological Sciences.

\r\n

\r\n It takes between 10 and 15 years and costs between $1.5 and $2.0 billion to bring a new drug to market, researchers noted, and about half of this time and capital is dedicated to clinical trials.

\r\n

\r\n But despite significant investments, clinical trials still have high failure rates, the team stated.

\r\n

\r\n Clinical trial failures are mainly due to poor recruiting and selecting techniques, as well as an inability to effectively monitor patients. Artificial intelligence tools have emerged as a viable way to improve these processes and increase clinical trial success rates, researchers said.

\r\n

\r\n “AI is not a magic bullet and is very much a work in progress, yet it holds much promise for the future of healthcare and drug development,” said lead author and computer scientist Stefan Harrer, a researcher at IBM Research-Australia.

\r\n

\r\n There are three types of AI being deployed by life science businesses which can provide a framework for improving efficiencies. Very broadly, AI can support 1) automation of a 

\r\n
  • Track 11-110.1 Process Automation / Focus on Efficiencies
  • Track 11-210.2 AI Driven Data Analysis / Focus on Precision of Go / No Go Decision
  • Track 11-310.3 AI and Insight into the Data /Focus on Business Decisions

\r\n Providing state-of-the-art care for people with brain and nervous system disorders is our most important commitment. As a neurology or neurosurgery patient at Cedars-Sinai,have a access to clinical trials and research aimed at improving testing methods, treatments, quality of life and recovery. These studies are open to people with a broad range of neurological conditions.

\r\n

\r\n  

\r\n

\r\n Controlled clinical trials are conduct the research that completes the causal argument between a treatment and a disease’s control. Yet, this pinnacle of a clinical research is itself afflicted. Chronic problems with the recruitment failure vitiate the potency of our research efforts. In addition, the collision of end-point multiplicity (the drive to measure multiple end points) with the requirement of statistical parsimony (ie, the need to reduce the number of interpretable end points to control the overall type I error) induces a core inefficiency in clinical trial productivity by reducing the number of endpoints findings that are generalizable to the population at large. Unless a clinical trial lists engage these problems with the vigor and imagination, our pinnacle may be a nothing more than an inflection point leading to decline.

\r\n

\r\n  

\r\n
  • Track 12-111.1 Effects of ODM-109 in ALS
  • Track 12-211.2 Amyotrophic Lateral Sclerosis (ALS)
  • Track 12-311.3 Genomic Translation for ALS Care (GTAC)
  • Track 12-411.4 The Use of Airway Clearance Devices in ALS
  • Track 12-511.5 Brainstorm Clinical Trial for ALS

 Clinical trials are the backbone of a modern day medicine. Randomized, double-blinded, placebo-controlled studies are critical for advancement in medicine and dermatology. Skin conditions such as psoriasis and atopic dermatitis are  the most common health problems in the United States. The Clinical trials  which can provide a treatments  not only the offer objective improvements in clinical disease status and also subjective improvements in the quality life of the patients for those who are afflicted with the disease.. In this article, we discuss the processes and resources of a clinical trials unit and the challenges that can be encountered during the study process. It is critical to engage  the clinical trials most effectively which to treat a patients with a new and innovative therapies which  are rooted in trial-validated,and evidence-based medicine.

 

 Clinical Trials in Oncology provides a concise, nontechnical, which is thoroughly up-to-date review methods and also issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have a separate chapters and expanded discussions on a general clinical trials issues, and the issues specific to Phases I, II, and III.New sections cover innovations in Phase I designs, randomized Phase II designs, and overcoming the challenges of array data

 

  • Track 13-112.1 Challenges of the clinical trails design
  • Track 13-212.2 Development of an Evidence-Based Decision Aid for Acne Treatment
  • Track 13-312.3 Need for Impartial Data Custodians and Verifiable

\r\n The globalization of a clinical research is a generally late wonder, in which a large portion of these reviews are occurring on a worldwide scale, with a huge increment of the clinical trials in creating nations. Created showcases in the United States, Western Europe, Germany, Japan still produce the lion's share of a clinical trial action. About 31% of a world's clinical trials are apparently directed outside of the United. As indicated by the report China, Japan, India, and Korea are the most dynamic settings for the clinical trials among creating countries. It is anticipated that the Japan as the world's second-biggest pharmaceutical market by 2015.

\r\n

\r\n As per the Clinical trials.gov the aggregate number of studies enlisted in 2016 is 231,756. The rate of studies enlisted from United States is 37%, Non-U.S is 47%. It is evaluated to achieve more than 280,000 review registries by 2017

\r\n

\r\n  because, for example, it gives to access to new treatments to participants; however, it requires discussion and the monitoring of ethical questions related mainly to ensuring the integrity.

\r\n

\r\n  

\r\n
  • Track 14-113.1 Globalization of drug development
  • Track 14-213.2 Ethical and scientific implications
  • Track 14-313.3 Comparative impact of globalization
  • Track 14-413.4 Mutual recognition of clinical study results
  • Track 14-513.5 Strategies for successful globalization of clinical trials

\r\n With the  increased in  clinical R&D and a budgetary constraints in the complexities of a clinical development,a risk management has become an essential and integral piece to a clinical trial management to ensure the good return on the investment. The core of a risk management is a identification and  assessment of a risks in the beginning and  it is also continuous basis for a risk-bearing activities in clinical trial. After issuance of a guidance on a Risk-Based Monitoring by FDA, the sponsors/CROs have demonstrated a keen interest in adopting a systematic approach to a risk assessment in clinical trials.

\r\n

\r\n Risk assessment is a systematic process for identifying and evaluating events that could be affect the achievement of the clinical study objectives.These documents include FDA’s “Guidance for Industry: Oversight of a Clinical Investigations—A Risk-Based Approach is to Monitoring” and EMA’s “Reflection paper on risk based quality management in the clinical trials”. The focus of the regulators on this concept initiates a discussion of how to introduce and implement, to apply risk management principles to the clinical trials. The applicable guidances for the good clinical practice (GCP), ICH E6 and ISO14155, it state explicitly that the sponsor is responsible for quality assurance and quality control.Risk management concepts can be extracted from  ISO 14971: Risk Management for Medical Devices and ICH Q9: Quality Risk Management. The first step is to define a procedure for conducting this activity. The basic steps for risk management include:the identify and assess risks, mitigate risks, and review risks. Additional steps that are required throughout the process include a communication of risks and a documentation activities

\r\n
  • Track 15-114.1 Identify and Assess Risks
  • Track 15-214.2 Mitigate Risks
  • Track 15-314.3 Communicate and Document Risks
  • Track 15-414.4 Assess the root causes risks and tolerance limits
  • Track 15-514.5 Assess the likelihood and impact of the risks